Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2017; 13(12): 1229
DOI: 10.1055/s-0036-1591619
DOI: 10.1055/s-0036-1591619
Synthesis of Natural Products and Potential Drugs
Asymmetric Synthesis of Ipatasertib
Further Information
Publication History
Publication Date:
17 November 2017 (online)
Key words
Ipatasertib - Akt kinase inhibitor - biotransformation - nitrilase-catalyzed resolution - ketoreductase reduction - asymmetric hydrogenationSignificance
Ipatasertib (GDC-0068) is an Akt kinase inhibitor that that is of interest for the treatment of cancer. The stereogenic centers in fragment F were installed using a nitrilase-catalyzed resolution of nitrile (rac)-A and a ketoreductase-catalyzed reduction of ketone D. For a related large-scale synthesis of Ipatasertib, see: T. Remarchuk et al. Org. Process Res. Dev. 2014, 18, 1652.
#
Comment
The stereogenic center in fragment L was installed by asymmetric hydrogenation. Using [Ru(TFA)2((S)-BINAP)] with catalyst activation by NaBr as an additive, allowed for S/C = 10,000. The optimal ratio to ensure reaction robustness was Ru/NaBr = 1:20 and thus afforded >99% conversion and 98.8:1.2 er.
#
#